'Perplexed' Depomed seeks mediation with Abbott on PHN drug
This article was originally published in Scrip
Executive Summary
While investors took little notice last spring when Depomed's partner Abbott filed a new drug application (NDA) with the US FDA for DM-1796, an extended-release, once-daily tablet formulation of gabapentin developed to treat postherpetic neuralgia (PHN), Wall Street was abuzz 19 January when news broke that the marriage between the firms may be over.